Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trialKentaro Tanaka, Isamu Okamoto, Takahiro Uchida et al.|European Journal of Cancer|2021Cited by 50
P2.23-02 Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A)Naoki Furuya, K. Takahashi, Kiyonori Miura et al.|Journal of Thoracic Oncology|2023Cited by 2